Navigation Links
Genetic mutation found in peripheral artery disease
Date:2/22/2008

The finding, appearing online in the journal Circulation, is the first to document a genetic mutation linked to PAD. Although the work was done in mice, researchers say it is likely to give them new insight into how PAD develops and progresses in humans.

Dr. Brian Annex, professor of medicine and director of vascular medicine at Duke, says the study stemmed directly from his clinical experience. Over and over, Id see two patients show up at the same time. They would be the same sex, same age, have identical risk factors and have similar blockages in their arteries. One of them would experience very slow progression of the disease, while the other would face limb loss or death within six months. I just knew there just had to be a genetic basis for it.

Peripheral arterial disease occurs when major arteries in the legs become clogged with plaque, a fatty build-up thats similar to the deposits in coronary arteries that can lead to a heart attack. Symptoms range from leg pain brought on by walking that goes away with rest thats the more benign form of the disease to a more serious form, marked by continuous pain and sores and ulcers on the legs that often lead to amputation.

Annex says the mild form rarely progresses into the more severe form. In reality, we may be looking at two types of diseases, although weve always thought of PAD as one.

Annex had the perfect participants for the study right at his fingertips: two strains of mice with surgically-induced blocked blood flow that mimicked human response to PAD. One strain recovered well, showing restored blood flow and little tissue death; the other had greater tissue loss and poor recovery of normal blood flow.

In collaboration with Dr. Douglas Marchuk, a professor of molecular genetics and microbiology at Duke, researchers crossbred the two strains and eventually isolated a mouse that enabled them to identify a relatively small region on chromosome 7 that app
'/>"/>

Contact: Michelle Gailiun
michelle.gailiun@duke.edu
919-660-1306
Duke University Medical Center
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Many Parents Share Genetic Test Findings With Kids
2. Genetic predisposition increases childhood asthma risk
3. New Alzheimers findings: High stress and genetic risk factor lead to increased memory decline
4. Test Spots Genetic Damage Done by Smoking
5. Scientists demonstate link between genetic variant and effectiveness of smoking cessation meds
6. Scientists highlight benefits of genetic research in sport, but warn of ethical concerns
7. Genetics Hold Promise, Challenges for Cancer Care
8. Researchers genetically engineer micro-organisms into tiny factories
9. Study Questions Genetic Screening for Treatable Diseases
10. Researchers provide genetic associations from a genome-wide scan for cardiovascular disease traits
11. Genetic variation affects smoking cessation treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... Parker Waichman LLP, a national law ... by defective drugs, has filed a lawsuit on behalf ... of the diabetes drug medication Actos (pioglitazone) caused ... 30, 2013, in the U.S. District Court for the ... is one of thousands of cases pending in the ...
(Date:5/20/2013)... 2013 Leading facial plastic surgeon and ENT ... a “Top Doc” in the field of Otolaryngology in the ... The Palm Beacher magazine, one of Palm Beach County’s leading ... the May/June 2013 issue, including 70 of the very best ... events, things to do, health and fitness, people to watch, ...
(Date:5/20/2013)... Mirena IUD lawsuit claims ... recently established in U.S. District Court, Southern District of ... court records, the litigation’s first Status Conference was held ... leadership positions were discussed. So far, at least ... of New York, all of which allege that the ...
(Date:5/20/2013)... 20, 2013 The Environmental ... feature dozens of continuing education credit opportunities for ... Institute of Architects Continuing Education System (AIA/CES), the ... the Interior Design Continuing Education Council (IDCEC). ... 1, 2013 at the Omni Providence Hotel in ...
(Date:5/20/2013)... 2013 Salt Lake Community College’s Know Greater ... Select 25 winners for 2013. As part of the ... Greater Heroes is a leadership training program that involves SLCC ... how to eat right, be active, and avoid drugs and ... Greater Heroes program each year, and visit more than 30 ...
Breaking Medicine News(10 mins):Health News:Taking Actos for Two Years Caused Bladder Cancer, Alleges Lawsuit Filed by Parker Waichman LLP on Behalf of South Dakota Man 2Health News:Dr. Schwartz Named “Top Doc” by The Palm Beacher Magazine 2Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Reports on First Status Conference in Federal Mirena Litigation 2Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Reports on First Status Conference in Federal Mirena Litigation 3Health News:Environmental Design Research Conference to Feature AIA/CES, LA CES, and IDCEC Continuing Education Credits 2Health News:SLCC Know Greater Heroes Program Named to Select 25 2Health News:SLCC Know Greater Heroes Program Named to Select 25 3
... and binge eating , MONDAY, May 10 (HealthDay News) ... the risk of impulse control disorders, such as problem ... In a new study that included 3,090 patients being ... the United States and Canada, the researchers found that ...
... ... Health Services, Inc. (CV10-2011), asserts that Gentiva, which employs some 30,000 health care workers, treats ... FLSA and refuses to pay these employees for all hours worked. , ... New York, NY (PRWEB) May 10, 2010 -- ...
... . Montreal, May 10, 2010 As fewer people ... among North American youth. A study published in the journal ... Montreal had used waterpipes (also known as shishas or hookahs) in ... due in part to perceptions that they are safer than cigarettes. ...
... Nurse staffing ... newly adopted U.S. Health Care Reform legislation. Current healthcare reform legislation indicates that more ... , ... (PRWEB) May 10, 2010 -- Nurse staffing agency, FlexRN, announces its plans to help agency ...
... treatment even when pulmonary disease looks stable, researchers ... of chronic obstructive pulmonary disease (COPD) leads to increased ... study finds. , British researchers looked at 25,857 COPD ... and 633 ischemic strokes (blockage of blood flow to ...
... from the Georgetown Lombardi Comprehensive Cancer Center at Georgetown ... therapy to "rescue" treatment sensitivity to fulvestrant in estrogen ... on May 15, 2010 as the cover story of ... common second-line therapy for women whose cancer progresses following ...
Cached Medicine News:Health News:Parkinson's Drugs Tied to Compulsive Behaviors 2Health News:Martin & Jones Announces Class Action Lawsuit Against Major Employer, Claims Thousands of Visiting Nurses Illegally Denied Overtime Pay 2Health News:Martin & Jones Announces Class Action Lawsuit Against Major Employer, Claims Thousands of Visiting Nurses Illegally Denied Overtime Pay 3Health News:FlexRN Nurse Staffing Agency Prepares Nurses for Demands of Latest Health Care Reform 2Health News:Researchers discover new way to 'rescue' treatment sensitivity of breast cancer cells 2
(Date:5/20/2013)...  Atlantic Pharmaceuticals, Inc., a specialty pharmaceutical company ... technology to deter prescription drug abuse today announced ... Soscia , has been chosen as a ... Health-Care Heroes Awards. The awards are presented annually ... individuals and organizations demonstrating excellence and deserving recognition ...
(Date:5/20/2013)... 2013 Enrollment of patients with Type 2 ... clinical trial of product candidate NewMet ™, a ... Type 2 diabetes. Elcelyx expects to complete enrollment of ... Results of the trial,s primary endpoint of change in ... the read-out for long-term glucose lowering and weight benefits ...
(Date:5/20/2013)... ROCKVILLE, Md. , May 20, 2013  Neuralstem, ... Eva Feldman , MD, PhD, principal investigator, presented ... neural stem cell (NSI-566) trial in the treatment of ... ,s disease) at the neuro diabetes special medical ... Friday. In a talk called "Recent Therapeutic Advances in ...
Breaking Medicine Technology:Atlantic Pharmaceuticals President Named Health Care Hero Finalist in Atlanta Business Chronicle for Drug Abuse Deterrent Technology 2Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 2Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 3Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 4Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 2Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 3Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 4
... , PLEASANTON, Calif., Dec. 2 Roche (SIX: RO, ROG; ... Drug Administration (FDA) approved an additional intended use for its ... comprised of up to 96 individual donations. The test, called ... cobas s 201 system, is a qualitative, in-vitro test ...
... , EAST HANOVER, N.J., Dec. ... late-breaking presentation on Tasigna® (nilotinib) 200 mg capsules in a ... company,s hematology portfolio in advancing the care of patients. ... Hematology (ASH) Annual Meeting and Exposition, highlight the company,s current ...
Cached Medicine Technology:FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus 2FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 2Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 4Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 5Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 7Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 8Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 9Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 10Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 11Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 12Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 13Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 14Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 15Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 16Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 17Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 18Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 19Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 20Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 21Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 22Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 23Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 24Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 25
... The MEL 80 is a top quality ... the correction of vision defects even safer, ... of this ultramodern work platform are oriented ... and the rapid recovery of vision. Key ...
An aid for advancing a pacemaker lead through the subcutaneous tissue of the chest wall to the pacemaker pocket....
An aid for advancing a pacemaker lead through the subcutaneous tissue of the chest wall to the pacemaker pocket....
... Escort Controller can be mounted at the ... table top. The design retains many ... controller, such as the pump drive motor ... pump, and infusion system. Retaining these ...
Medicine Products: